Recursion Pharmaceuticals: I’m Still Bearish Despite Recent Genentech News (NASDAQ:RXRX)
· seekingalpha.com
Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.
Recursion Pharmaceuticals, Inc. ( RXRX ) was founded in 2013 and is based in Salt Lake City, Utah. The company describes its approach as "the future of AI drug ...